IN THE NEWS

.

IN THE NEWS

 

Poïesis Opens Seed Round Seeking $5 Million

Poïesis Opens Seed Round Seeking $5 Million

Following on its move from London to San Diego, California, Poïesis has opened its Seed Round of financing seeking to raise $5 million to complete in-licensing and initiate clinical development of its therapeutic and diagnostic pipeline in several indications in dogs,...

A Tale of Two Acquisitions

A Tale of Two Acquisitions

By Joseph Harvey, 20 April 2017. So far, 2017 has said farewell to Merial and seen the purchase of Nexvet Biopharma – two very different companies in the animal health space. Animal Pharm editor Joseph Harvey takes a closer look at these two transactions and their...

Pet Meds Adapted from Human Therapies

Pet Meds Adapted from Human Therapies

Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market. By Jenny Rood | October 1, 2016. Around Christmas 2010, University of Minnesota researcher Mark Suckow received terrible news:...

Why Pet Health Is The Focus Of A New Biotech Sector

Why Pet Health Is The Focus Of A New Biotech Sector

By Cathy Yarbrough, Contributing Editor   For Aratana Therapeutics, 2016 was a banner year. The biotech company, founded in 2010, achieved FDA approvals for three of its 10 pipeline drugs. Last year the Kansas City-based company also forged a global partnership...

Treating Cancer in Dogs Provides Hope for Humans

Treating Cancer in Dogs Provides Hope for Humans

Provides Hope for Humans When Krista DeZerega-Thomson got the dreaded news that Rohan, the family’s beloved Labrador retriever, had cancer, she was devastated. He had metastatic melanoma—an aggressive form that affects dogs and humans—and was given only two months to...

.